Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers. 29 papers were listed this time. Here's a handful in our areas of our research interest:
Campbell HE, Epstein D, et al. The cost-effectiveness of adjuvant chemotherapy for early breast cancer: A comparison of no chemotherapy and first, second, and third generation regimens for patients with differing prognoses. Eur J Cancer. 2011 Jul 7. [Epub ahead of print] PubMed PMID: 21741831.
Sullivan SD, Garrison LP, Rinde H, Kolberg J, Moler EJ. Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. J Med Econ. 2011 Jul 11. [Epub ahead of print] PubMed PMID: 21740291.
Kobelt G, Lekander I, Lang A, et al. Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. Int J Technol Assess Health Care. 2011 Jul 8:1-8. [Epub ahead of print] PubMed PMID: 21736857.
Lazar LD, Pletcher MJ, Coxson PG, et al. Cost-effectiveness of statin therapy for primary prevention in a low-cost statin era. Circulation. 2011 Jul 12;124(2):146-53. Epub 2011 Jun 27. PubMed PMID: 21709063.
Mueller D, Gandjour A. Cost Effectiveness of Secondary vs Tertiary Prevention for Post-Menopausal Osteoporosis. Appl Health Econ Health Policy. 2011 Jul 1;9(4):259-73. PubMed PMID: 21682353.
